UNSPSC 51362405: Homofenazine dihydrochloride

This classification denotes a sedative and hypnotic with the molecular formula C23H28F3N3OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L5JN11UQL, chemically known as 2-trifluoroethyl-10-(3-(4-(beta-hydroxyethyl-1-hexahydro-1,4-diazepinyl)propyl)phenothiazine but more generally known as homofenazine dihydrochloride, which bears US NIH Compound Identifier 19687. European Medicines Agency schedules Homofenazine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02537MIG.

Most nations, for tariff and trade purposes, schedule homofenazine dihydrochloride under HS 29343090 and SITC 51578. As of Q4 2014, HOMOFENAZINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)N(C3CC(CCC3S2)C(F)(F)F)CCCN4CCCN(CC4)CCO.CL.CL.

UNSPSC 51362405 Homofenazine dihydrochloride is a Commodity code with minimal recent activity under state and local procurement; the code's pharmaceutical-chemistry specificity does not align with the broader pharmaceutical-supply and health-system purchases that jurisdictions are actually soliciting under related classifications. The recent opportunities tagged to this code show that state and local governments are buying naloxone and drug-deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and exploring direct-to-manufacturer prescription programs, but these purchases span much broader product families than the single chemical compound named in the code. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance), reflecting a mix of county-level community health procurement and state-level pharmacy benefit program management.

The geographic spread includes Florida, Texas, and Minnesota, with the Minnesota procurement extending to participating state and local facilities in Oregon as well. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2023; Texas HHS Commission's RFI on direct-to-manufacturer prescription programs, closing April 3, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with contract effectiveness July 1, 2026. The mismatch between the code's chemical name and the scope of recent opportunities signals that this code sees limited real-world procurement activity under its narrow specification.